A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS

BCT-002-US

This study will evaluate the safety and efficacy of repeated administration of NurOwn® (MSC-NTF cells) therapy, which is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are enriched from the patient's own bone marrow, propagated ex vivo and induced to secrete Neurotrophic factors (NTFs). The autologous NurOwn® (MSC-NTF cells) are back-transplanted into the patient intrathecally by standard lumbar puncture where neurons and glial cells are expected to take up the neurotrophic factors secreted by the transplanted cells

2017-08-28

2020-09-29

2020-09-29

Completed

Early phase I

196

Inclusion Criteria: * ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria. * Having onset of ALS disease symptoms, including limb weakness within 24 months at the Screening Visit. * ALSFRS-R ≥ 25 at the screening Visit. * Upright slow vital capacity (SVC) measure ≥ 65% of predicted for gender, height, and age at the screening Visit. * Rapid progressors * Participants taking a stable dose of Riluzole are permitted in the study * Citizen or permanent resident of the United States or Canadian citizen able to travel to a US site for all follow-up study visits Exclusion Criteria: * Prior stem cell therapy of any kind * History of autoimmune or other serious disease (including malignancy and immune deficiency) that may confound study results * Current use of immunosuppressant medication or anticoagulants (per Investigator discretion) * Exposure to any other experimental agent or participation in an ALS clinical trial within 30 days prior to Screening Visit * Use of RADICAVA (edaravone injection) within 30 days of screening or intent to use edaravone at any time during the course of the study including the follow up period * Use of non-invasive ventilation (BIPAP), diaphragm pacing system or invasive ventilation (tracheostomy) * Feeding tube * Pregnant women or women currently breastfeeding

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Randomized, Double-Blind, Placebo-Controlled Multicenter Study', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'This is a double-blind study where the investigators, participants and all sponsor and CRO personnel involved in the conduct, data management or analysis of the study will remain blinded to the treatment assignments', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 196, 'type': 'ACTUAL'}}

2024-02-29